Glioblastoma heterogeneity at single cell resolution

D Eisenbarth, YA Wang - Oncogene, 2023 - nature.com
Glioblastoma (GBM) is one of the deadliest types of cancer and highly refractory to
chemoradiation and immunotherapy. One of the main reasons for this resistance to therapy …

Overview of current targeted therapy in gallbladder cancer

X Song, Y Hu, Y Li, R Shao, F Liu, Y Liu - Signal Transduction and …, 2020 - nature.com
Gallbladder cancer (GBC) is rare, but is the most malignant type of biliary tract tumor.
Unfortunately, only a small population of cancer patients is acceptable for the surgical …

Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures

LS Hu, F D'Angelo, TM Weiskittel, FP Caruso… - Nature …, 2023 - nature.com
Sampling restrictions have hindered the comprehensive study of invasive non-enhancing
(NE) high-grade glioma (HGG) cell populations driving tumor progression. Here, we present …

Evolution of experimental models in the study of glioblastoma: toward finding efficient treatments

R Gómez-Oliva, S Domínguez-García… - Frontiers in …, 2021 - frontiersin.org
Glioblastoma (GBM) is the most common form of brain tumor characterized by its resistance
to conventional therapies, including temozolomide, the most widely used chemotherapeutic …

Detection of TERT Promoter Mutations as a Prognostic Biomarker in Gliomas: Methodology, Prospects, and Advances

T Hasanau, E Pisarev, O Kisil, N Nonoguchi… - Biomedicines, 2022 - mdpi.com
This article reviews the existing approaches to determining the TERT promoter mutational
status in patients with various tumoral diseases of the central nervous system. The …

Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas

L Scheetz, P Kadiyala, X Sun, S Son… - Clinical Cancer …, 2020 - AACR
Purpose: Gliomas are brain tumors with dismal prognoses. The standard-of-care treatments
for gliomas include surgical resection, radiation, and temozolomide administration; however …

Personalised therapeutic approaches to glioblastoma: A systematic review

OD Mowforth, J Brannigan, M El Khoury… - Frontiers in …, 2023 - frontiersin.org
Introduction Glioblastoma is the most common and malignant primary brain tumour with
median survival of 14.6 months. Personalised medicine aims to improve survival by …

Effectiveness and safety of pyrotinib, and association of biomarker with progression-free survival in patients with HER2-positive metastatic breast cancer: a real-world …

Q Chen, D Ouyang, M Anwar, N Xie, S Wang… - Frontiers in …, 2020 - frontiersin.org
Background: Pyrotinib, an irreversible pan-ERBB inhibitor, has shown promising antitumour
activity, and acceptable tolerability. This research was conducted to evaluate the actual use …

Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning

XP Liu, X Jin, S Seyed Ahmadian, X Yang… - Neuro …, 2023 - academic.oup.com
Background Lower-grade gliomas (LGG) are heterogeneous diseases by clinical,
histological, and molecular criteria. We aimed to personalize the diagnosis and therapy of …

[HTML][HTML] Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models

LT Rodgers, JL Villano, AMS Hartz, B Bauer - Cancers, 2024 - mdpi.com
Simple Summary Glioblastoma is the most common and aggressive brain tumor in adults.
Despite surgery, radiation, and chemotherapy, survival rates remain low, which emphasizes …